A Perspective on the Cost-Benefit of Drug Therapy

References

• Anon. Pharmaceutical Manufacturers Association Newsletter August 2, 1982
   Google Scholar
• U. S. Department of Health and Human Services. Prescribed Medicines: Use, Expenditures and Sources of Payment. National Center for Health Services Research. DHHS Publication No. (PHS) 823320, 1982
   Google Scholar
• Glaser M. Rx drug sales bloom despite economic climate. Drug Topics 1983; 127: 34–35
   Google Scholar
• Smith MC, Knapp DA. Pharmacy, Drugs and Medical Care, Third edition. Williams and Wilkins, Baltimore 1981
   Google Scholar
• Anon. Self-Medication: The New Era. Proprietary Association, Washington, DC 1983
   Google Scholar
• U. S. Department of Health, Education and Welfare. Healthy People The Surgeon's Report on Health Promotion and Disease Prevention, Background Papers. 1979, DHEW Publication No. 79–55071A, Washington, D.C.
   Google Scholar
• U. S. Department of Health and Human Services. The Illness Burden That Prevention Could Reduce. Health-United States 1980. DHEW Publication No. 81–1232, December, 1980
   Google Scholar
• Johnson KA. Hospital economic forecast. Hospitals 1983; 1: 73–76
   Google Scholar
• McGhan W., Rowland C., Bootman JL. Cost-benefit and cost-effectiveness: methodology for evaluating clinical pharmacy services. Am J Hosp Pharm 1978; 35: 133–40
   PubMedGoogle Scholar
• Bootman JL, Rowland C., Wertheimer A. Cost-benefit analysis: a research tool for evaluating innovative health programs. Eval Health Professions 1979; 2: 129–54
   PubMedGoogle Scholar
• Weinstein MC, Stason B. Foundations and cost/effectiveness analysis for health and medical practitioners. N Engl J Med 1977; 296: 716–21
   PubMed Web of Science ®Google Scholar
• Shepard DS, Thompson MS. First principles of cost-effectiveness analysis in health. Public Health Rep 1979; 94: 535–44
   PubMed Web of Science ®Google Scholar
• Crystal R., Brewster A. Cost-benefit and cost-effectiveness analysis in the health field: an introduction. Inquiry 1966; 3: 3–13
   Google Scholar
• Acton J. Measuring the monetary value of life-saving programs. Law Contemp Prob 1976; 40: 46–72
   Google Scholar
• Emlet HE, Jr. Use of cost-benefit analysis in solutions to national health problems. Presented at the 1968 Joint National Meeting of the Operations Research Society of America. May 1–3, San Francisco, CA 1968
   Google Scholar
• Gellman DD. Cost-benefit in health care: we need to know more. Can Med Assoc J 1974; 3: 998–99
   Google Scholar
• Goldschmidt PG. A cost/effectiveness model for evaluating health care programs: application to drug abuse treatment. Inquiry 1976; 13: 29–47
   PubMedGoogle Scholar
• Bootman JL, Wertheimer A., Zaske D., Rowland C. Individualizing gentamicin dosage regimens on burn patients with gram-negative septicemia: a cost-benefits analysis. J Pharm Sci 1979; 68: 267–72
   PubMed Web of Science ®Google Scholar
• Bootman JL, Zaske D., Wertheimer AL, Rowland C. Individualization of aminoglycoside dosage regimens: a cost analysis. Am J Hosp Pharm 1979; 36: 368
   PubMedGoogle Scholar
• Strange PV, Sumner AT. Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 1978; 298: 372–78
   PubMed Web of Science ®Google Scholar
• Cretin S. Cost/benefit analysis of treatment and prevention of myocardial infarction. Health Serv Res 1977; 12: 174–89
   PubMed Web of Science ®Google Scholar
• Mattsson W., Glynning I., Carlsson B., Mauritzon SE. Cancer chemotherapy in advanced malignant disease: a cost-benefit analysis. Acta Radiol Oncol 1979; 18: 509–20
   Google Scholar
• Stason W., Weinstein M. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732
   PubMed Web of Science ®Google Scholar
• Estershan RJ, Jr, Vogal VG, Fortner CL, Shapiro HM, Wiernik PH. Cost analysis fo leukemia treatment: a problem-oriented approach. Cancer 1976; 37: 646–52
   PubMed Web of Science ®Google Scholar
• Bryers F., Hawthorne VM. Screening for mild hypertension: costs and benefits. J Epidemiol Commun Health 1978; 32: 171–74
   PubMed Web of Science ®Google Scholar
• Kissick WL. Cost-benefit studies in health planning in the U.S.A. Health Economics. 1969; 39–44, Copenhagen
   Google Scholar
• Klarman H. Application of cost/benefit analysis to health services and the special case of technological innovation. Int J Health Serv Res 1974; 4: 325–52
   PubMed Web of Science ®Google Scholar
• Klarman H. Present status of cost-benefit analysis in the health field. Am J Public Health 1967; 57: 1948–58
   Web of Science ®Google Scholar
• Smith W. Cost/effectiveness and cost/benefit for public health programs. Public Health Rep 1968; 83: 899–906
   PubMed Web of Science ®Google Scholar
• Mushkin S., D'Accolings F. Economic cost of disease and injury. Public Health Rep 1959; 74: 338–45
   PubMedGoogle Scholar
• Pigou AC. Socialism Versus Capitalism. Macmillan Press, London 1947; 129
   Google Scholar
• Prest AR, Turvey R. Cost-benefits analysis: a survey. Econ J 1965; 75: 683–735
   Web of Science ®Google Scholar
• Quade ES. Introduction and Overview. Cost/Effectiveness Analysis, TA Goldman. Praeger, New York 1967; 1
   Google Scholar
• Vracin RA. Decision models for capital investment and financing decisions in hospitals. Health Serv Res 1980; 15: 35–52
   PubMed Web of Science ®Google Scholar
• Rice DP. Measurement and application of illness costs. Public Health Rep 1969; 84: 95–101
   PubMed Web of Science ®Google Scholar
• Reifman A., Wyatt RJ. Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry 1980; 37: 385–88
   PubMed Web of Science ®Google Scholar
• Hannan EL, Graham JK. A cost-benefit study of a hypertension screening and treatment program at the work setting. Inquiry 1978; 15: 345–58
   PubMedGoogle Scholar
• Schoenbaum SC, Hyde JN, Bantoshesky L., Crampton R. Benefit-cost analysis of rubella vaccination policy. N Engl J Med 1976; 294(6)306–10
   PubMed Web of Science ®Google Scholar
• Weisbrod BA. Costs and benefits of medical research: a case study poliomyletis. J Pol Econ 1971; 79: 527–44
   Web of Science ®Google Scholar
• Amadio J., Mueller J., Casey R. Benefit/Cost Ratios in Public Health. Illinois Department of Public Health, Southern Illinois University, Carbondale and Jackson County Health Department, August 1976
   Google Scholar
• Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303(10)553–80
   PubMed Web of Science ®Google Scholar
• Ricardo-Campbell R., Isman MM, Wandell WM, Crossky R. Preliminary methodology for controlled cost-benefit study of drug impact: the effect of eimetidine on days of work lost in a short-term trial duodenal ulcer. J Clin Gastroenterol 1980; 2: 37–41
   PubMed Web of Science ®Google Scholar
• Netherlands Economic Institute. Present Cost of Peptic Ulceration to the Dutch Economy and Possible Impact of Cimetidine on this Cost. 1977, Rotterdam
   Google Scholar
• Institute of Political Economic Studies. Assessment of the Social Benefits Deriving from the Introduction of Cimetidine in Italy. University of Pavia, Italy 1978
   Google Scholar
• Robinson Associates, Inc. The Impact of Cimetidine on the National Cost of Duodenal Ulcer. Bryn Mawr, PA 1978
   Google Scholar
• Culyer AJ, Maynard AK. Cost-effectiveness of duodenal ulcer treatment. Soc Sci Med 1981; 15c: 3–11
   Google Scholar
• Geweke JF, Weisbrod BA. Some economic consequences of technological advance in medical care: the case of a new drug. Drugs and Health: Economic Issues and Policy Objectives, RD Helms. Institute for Public Policy Research, Washington, D.C. 1981, The American Enterprise
   Google Scholar
• Gross SM, Sciarra JJ. Why it's important to analyze drugs' cost-effectiveness. Pharmacy Times. 1980, October.
   Google Scholar
• Sackett DL, Haynes RB. Compliance with Therapeutic Regimens. Baltimore, Johns Hopkins University Press 1976
   Google Scholar